Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 4, 2011, Pages 420-427

  Lönnkvist, Maria H ^a   Theodorsson, Elvar ^b   Holst, Mikael ^a   Ljung, Tryggve ^c   Hellström, Per M ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biological treatment; biomarkers; Harvey Bradshaw index; inflammatory bowel disease

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; ENDOTHELIN; GHRELIN; HIGH SENSITIVE C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; NITRITE; PREDNISOLONE; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ADULT; ARTICLE; BLOOD CHEMISTRY; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DRUG INFUSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HARVEY BRADSHAW INDEX; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE CYCLE TREATMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; ENDOTHELINS; FEMALE; GHRELIN; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; NITRITES; PREDICTIVE VALUE OF TESTS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 79952576846     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.539253     Document Type: Article

References (37)

1. Peyrin-Biroulet L, Loftus Jr EV, Colombel JF, Sandborn WJ. The natural history of adult Crohn'sdisease in populationbased cohorts. Am J Gastroenterol 2010;105:289-97.
2. Solberg IC, Vatn MH, Høle O, Stray N, Sauar J, Jahnsen J, et al. Clinical course in Crohn'sdisease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5:1430-8.
3. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492-500.
4. D'Haens G, Baert F, Van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7.
5. Ferrante M, D'Haens G, Rutgeerts P, Vermeire S, Van Assche G. Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn'sdisease). Curr Gastroenterol Rep 2009;11:504-8.
6. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn'sdisease. N Engl J Med 2010;362:1383-95.
7. Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008;57:1518-23.
8. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
9. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn'sdisease activity and Harvey-Bradshaw indices in assessing Crohn'sdisease severity. Clin Gastroenterol Hepatol 2010;8:357-63.
10. Schiessl B, Strasburger C, Bidlingmaier M, Mylonas I, Jeschke U, Kainer F, et al. Plasma- and urine concentrations of nitrite/nitrate and cyclic guanosinemonophosphate in intrauterine growth restricted and preeclamptic pregnancies. Arch Gynecol Obstet 2006;274:150-4.
11. Compher CW, Kinosian BP, Metz DC. Ghrelin does not predict adaptive hyperphagia in patients with short bowel syndrome. JPEN J Parenter Enteral Nutr 2009;33:428-32.
12. Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007;52:2063-8.
13. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55: 426-31.
14. Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008;14:85-9.
15. Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002;37:818-24.
16. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27: 793-8.
17. Reinders CA, Jonkers D, Janson EA, Stockbrügger RW, Stobberingh EE, Hellström PM, et al. Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease. Scand J Gastroenterol 2007;42:1151-7.
18. Ljung T, Lundberg S, Varsanyi M, Johansson C, Schmidt PT, Herulf M, et al. Rectal nitric oxide as biomarkerin the treatment of inflammatory bowel disease: responders versus nonresponders. World J Gastroenterol 2006;12: 3386-92.
19. Ljung T, Axelsson LG, Herulf M, Lundberg JO, Hellström PM. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment. Aliment Pharmacol Ther 2007;25:925-32.
20. Goggins MG, Shah SA, Goh J, Cherukuri A, Weir DG, Kelleher D, et al. Increased urinary nitrite, a marker of nitric oxide, in active inflammatory bowel disease. Mediators Inflamm 2001;10:69-73.
21. Webb A, Bond R, McLean P, Uppal R, Benjamin N, Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci USA 2004;101:13683-8.
22. Nandi J, Saud B, Zinkievich JM, Yang ZJ, Levine RA. TNF-alpha modulates iNOS expression in an experimental rat model of indomethacin-induced jejunoileitis. Mol Cell Biochem 2010;336:17-24.
23. Lonnkvist MH, Befrits R, Lundberg JO, Lundahl J, Fagerberg UL, Hjortswang H, et al. Infliximab in clinical routine: experience with Crohn's disease and biomarkers of inflammation over 5 years. Eur J Gastroenterol Hepatol 2009;21:1168-76.
24. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010;584:1923-30.
25. Eugen-Olsen J, Gustafson P, Sidenius N, Fischr TK, Parner J, Aaby P, et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002;6:686-92.
26. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000;96:4091-5.
27. Ostrowski SR, Ullum H, Goka BQ, Høyer-Hansen G, Obeng-Adjei G, Pedersen BK, et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005;191: 1331-41.
28. Slot O, Brünner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999;58:488-92.
29. Testa JE, Quigley JP. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev 1990;9:353-67.
30. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010;268:296-308.
31. Lomholt AF, Christensen IJ, Høyer-Hansen G, Nielsen HJ. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol 2010;49: 805-11.
32. De Smet B, Thijs T, Moechars D, Colsoul B, Polders L, Ver Donck L, et al. Endogenous and exogenous ghrelin enhance the colonic and gastric manifestations of dextran sodium sulphate-induced colitis in mice. Neurogastroenterol Motil 2009;21:59-70.
33. Sung E, Da Silva NF, Goodyear S, McTernan PG, Sanger GJ, Nwokolo CU. Increased plasma ghrelin following infliximab in Crohn's disease. Aliment Pharmacol Ther 2008;29:83-9.
34. Ates Y, Degertekin B, Erdil A, Yaman H, Dagalp K. Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig Dis Sci 2008;53: 2215-21.
35. Murch SH, Braegger CP, Sessa WC, MacDonald TT. High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet 1992;339:381-5.
36. Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, Kikuchi K. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 2001; 96:822-8.
37. McCartney SA, Ballinger AB, Vojnovic I, Farthing MJ, Warner TD. Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis. Life Sci 2002;71: 1893-904.